Talk:Hypereosinophilic syndrome

I
I would like information on the disease Hypereosinophilic Syndrome. Any type of information you have would be greatly apprecited.

Thank You Sandra Sawtelle

I have HES. I am lucky i guess in that my symptoms, although worrying sometimes, are largely pain free.Craftsmanship 17:50, 14 March 2007 (UTC)


 * Most symptoms of HES are not particularly painful. JFW | T@lk  21:21, 16 March 2008 (UTC)

I also was just diagnosed with HES (called HS by my doctors). The medication that I will be treated with is Glevec (Imatinib), as it has been approved for the use in treatment of HS by the FDA, and has been proven to improve or remove almost all symptoms of HS. Treatment via the use of Imatinib does require prior testing of your heart to make sure it hasn't been damaged by the HS as one the possible side-effects is heart damage. My particular variant of HS attacked my skin and joints, causing pain, rashes, lesions and other allergy / arthritis like symptoms for close to 4 years before finally being diagnosed correctly. My joint pains were nearly incapacitating (my Eos counts were in the 30k range), and my skin is scarred for life. UPDATE: Within 2 weeks of starting Imatinib, my eosinophil count was normal, my red blood cell count dropped significantly though, and had to have transfusions (2 units of RBC to bring me to just under 9), but has been slowly rising since then. Just started my 3rd month on the drug, and feeling better than I have in over 4 years. —Preceding unsigned comment added by 168.168.67.112 (talk) 06:31, 12 September 2009 (UTC)

Consensus document
is a consensus document from a few years ago that could serve as a reliable source for the classification of hypereosinophilic conditions. JFW | T@lk  21:21, 16 March 2008 (UTC)


 * Large trial (85 is really a lot) of Mepolizumab: http://content.nejm.org/cgi/content/full/NEJMoa070812 - can be added once the journal has been printed, I suppose. JFW | T@lk  22:16, 16 March 2008 (UTC)
 * Yep, just got the Online First article in my inbox. Mepolizumab could probably use a short section on it too :) Fvasconcellos (t·c) 00:58, 17 March 2008 (UTC)